| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/02/2005 | EP1502594A1 A health care composition for decreasing the risk of thrombosis including a mixture of proanthocyanidins and sesquiterpenes |
| 02/02/2005 | EP1502593A1 The use of Stanozolol for the preparation of anti-inflammatory and anti-degenerative drugs |
| 02/02/2005 | EP1502592A1 Controlled release oxycodone compositions |
| 02/02/2005 | EP1502591A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 02/02/2005 | EP1502590A1 Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes |
| 02/02/2005 | EP1502589A1 Veterinary aqueous injectable suspensions containing florfenicol |
| 02/02/2005 | EP1502588A1 Light-stabilized soft capsule for formulations |
| 02/02/2005 | EP1502587A1 Sustained release formulation for Venlafaxine hydrochloride |
| 02/02/2005 | EP1502586A1 Preparations for the application of anti-inflammatory agents |
| 02/02/2005 | EP1502576A2 Composition containing a 2-thioacetamide and use thereof for stimulating growth or preventing fall out of keratin fibres |
| 02/02/2005 | EP1502508A2 Synergistic microbicidal combinations |
| 02/02/2005 | EP1501948A1 A dna enzyme to inhibit plasminogen activator inhibitor-1 |
| 02/02/2005 | EP1501930A2 Oligomeric compounds for the modulation hif-1alpha expression |
| 02/02/2005 | EP1501925A2 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
| 02/02/2005 | EP1501923A2 Pak5-related compositions and methods |
| 02/02/2005 | EP1501919A1 Soya cell strains with high isoflavone content |
| 02/02/2005 | EP1501860A2 Modulation of heat-shock-protein-based immunotherapies |
| 02/02/2005 | EP1501859A1 17a-FLUOROALKYL-11BETA-BENZALDOXIME-STEROIDS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING SAID STEROIDS AND THE USE THEREOF IN THE PRODUCTION OF MEDICAMENTS |
| 02/02/2005 | EP1501858A2 Further syntheses of cyproterone acetate |
| 02/02/2005 | EP1501857A2 Novel pancortin-pablo protein interactions and methods of use thereof |
| 02/02/2005 | EP1501852A2 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 02/02/2005 | EP1501850A2 Nucleoside derivatives for treating hepatitis c virus infection |
| 02/02/2005 | EP1501847A2 11-deoxy azalide antibacterials |
| 02/02/2005 | EP1501846A1 Tricyclic macrolide antibacterial compounds |
| 02/02/2005 | EP1501845A1 Antibacterial compounds with improved pharmacokinetic profiles |
| 02/02/2005 | EP1501841A2 Non nucleoside reverse transcriptase inhibitors |
| 02/02/2005 | EP1501837A1 Cascade esters of camptothecins and methods of treating cancer using these compounds |
| 02/02/2005 | EP1501836A1 Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds |
| 02/02/2005 | EP1501835A2 2-(quinolonyl)-fused heterocycles as androgen receptor modulators |
| 02/02/2005 | EP1501834A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501833A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501830A1 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases |
| 02/02/2005 | EP1501829A1 Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase |
| 02/02/2005 | EP1501828A1 Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders |
| 02/02/2005 | EP1501827A2 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acid and their use as protease inhibitors |
| 02/02/2005 | EP1501826A2 Substituted indoles as alpha-1 agonists |
| 02/02/2005 | EP1501825A2 Substituted imidazolylmethyl pyridine and pyrazine derivatives: gaba a receptor ligands |
| 02/02/2005 | EP1501823A1 New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds |
| 02/02/2005 | EP1501819A1 Estrogen receptor modulators |
| 02/02/2005 | EP1501817A1 Imidazolinylmethyl aralkylsulfonamides |
| 02/02/2005 | EP1501815A1 Substituted phenylacetamides and their use as glucokinase activators |
| 02/02/2005 | EP1501814A1 Semicarbazide derivatives for combating thromboembolic diseases |
| 02/02/2005 | EP1501813A2 Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them |
| 02/02/2005 | EP1501812A1 Pna monomer and precursor |
| 02/02/2005 | EP1501809A1 Triazole derivatives as tachykinin receptor antagonists |
| 02/02/2005 | EP1501808A1 Tachykinin receptor antagonists |
| 02/02/2005 | EP1501807A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists |
| 02/02/2005 | EP1501806A1 Preparations for the topical application of anti-androgenically active substances |
| 02/02/2005 | EP1501804A1 Isoquinoline derivatives mao-b inhibitors |
| 02/02/2005 | EP1501803A2 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
| 02/02/2005 | EP1501801A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors |
| 02/02/2005 | EP1501800A1 Bombesin antagonists |
| 02/02/2005 | EP1501799A1 Compounds useful in preparing camptothecin derivatives |
| 02/02/2005 | EP1501798A2 SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS |
| 02/02/2005 | EP1501797A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo[b]thiophene-2-carboxylic acid derivatives as interleukin-4 gene expression inhibitors |
| 02/02/2005 | EP1501796A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo[b]thiophene-2-carboxylic acid derivatives as interleukin-4 gene expression inhibitors |
| 02/02/2005 | EP1501795A1 Cinnamic acid amides |
| 02/02/2005 | EP1501794A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors |
| 02/02/2005 | EP1501793A1 Tamsulosin derivative |
| 02/02/2005 | EP1501791A1 Amino acid analogues |
| 02/02/2005 | EP1501790A2 Novel sodium channel blockers |
| 02/02/2005 | EP1501787A1 N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists |
| 02/02/2005 | EP1501774A1 Polyunsaturated linear aldehydes and their derivatives with anti-radical and anti-tumoral activity |
| 02/02/2005 | EP1501605A1 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency |
| 02/02/2005 | EP1501567A1 Method and device for controlling drug pharmacokinetics |
| 02/02/2005 | EP1501566A1 Medical products comprising a haemocompatible coating, production and use thereof |
| 02/02/2005 | EP1501565A1 Compounds and method for coating surfaces in a haemocompatible manner |
| 02/02/2005 | EP1501550A1 Non-viral gene delivery system |
| 02/02/2005 | EP1501548A1 Chemically activated carboxypolysaccharides and uses |
| 02/02/2005 | EP1501547A1 Methods and conpositions for treating, preventing or delaying onset of a neoplasm |
| 02/02/2005 | EP1501545A2 Use of tnfalpha antibodies and another drug |
| 02/02/2005 | EP1501535A1 Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents |
| 02/02/2005 | EP1501530A2 Prostaglandin f2 alpha analogs in combination with antimicrobial for treating glaucoma |
| 02/02/2005 | EP1501528A1 Method for extracting a novel compound from the root of a plant of the pentadiplandraceae family |
| 02/02/2005 | EP1501526A1 Curcumin for the prevention and/or treatment of tissue damage |
| 02/02/2005 | EP1501525A1 Method for producing preparations rich in tocotrienol |
| 02/02/2005 | EP1501522A2 Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents |
| 02/02/2005 | EP1501521A1 Long acting compositions comprising zidovudine and lamivudine |
| 02/02/2005 | EP1501520A1 Pharmaceutical compositions for lowering blood glucose and blood cholesterol levels |
| 02/02/2005 | EP1501519A1 9-oxime macrolide antibacterials |
| 02/02/2005 | EP1501518A2 Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders |
| 02/02/2005 | EP1501517A1 Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention |
| 02/02/2005 | EP1501515A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501514A2 Protein kinase modulators and methods of use |
| 02/02/2005 | EP1501513A2 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
| 02/02/2005 | EP1501512A2 4-azasteroid derivatives as androgen receptor modulators |
| 02/02/2005 | EP1501511A1 Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway |
| 02/02/2005 | EP1501510A1 The treatment of pain with ifenprodil |
| 02/02/2005 | EP1501509A2 Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers |
| 02/02/2005 | EP1501508A1 Inhibitors of histone deacetylase |
| 02/02/2005 | EP1501507A2 Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| 02/02/2005 | EP1501506A1 Fxr agonists for hepatoprotection and treatment of cholestasis |
| 02/02/2005 | EP1501505A1 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h- 1,2,4 -t riazole for the treatment of autoimmune diseases |
| 02/02/2005 | EP1501504A1 1-substituted imidazole derivatives as nos inhibitors |
| 02/02/2005 | EP1501503A1 Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatment of central nervous system disturbances |
| 02/02/2005 | EP1501502A2 Carvedilol pharmasolve solvate |
| 02/02/2005 | EP1501500A2 Carvedilol formulations |
| 02/02/2005 | EP1501499A1 Trans-epicutaneous administration form for treating restless leg syndrome |
| 02/02/2005 | EP1501498A1 Pharmaceutical composition comprising a lipase inhibitor and glucomannan |
| 02/02/2005 | EP1501497A2 Catechin multimers as therapeutic drug delivery agents |